• Pfizer Inc., of New York, said top-line results from a Phase III study testing the 165-mg dose and the 330-mg dose of pregabalin controlled-release (CR) formulation in adults with partial onset seizures showed that the trial did not meet its primary endpoint comparing the change in seizure frequency to placebo, although both doses were well tolerated. The study is one of three Phase III trials designed to test pregabalin CR for use as a once-daily therapy. The other two studies are testing the drug in fibromyalgia and postherpetic neuralgia. Pfizer has marketed an immediate-release form of pregabalin, branded Lyrica, for adjunctive therapy in partial onset seizures since June 2005.